The number most commonly refers to a specific scientific guideline established by the European Medicines Agency (EMA) regarding the development of Gene Therapy Medicinal Products (GTMPs) .
: Assessing the risk of "insertional mutagenesis"—where the therapy might accidentally interfere with the patient's existing DNA. 125459
: Determining where the therapeutic gene goes in the body and how long it persists in both target and non-target cells. The number most commonly refers to a specific
: Defining scientific principles for non-clinical studies specifically for gene therapies, which differ significantly from conventional pharmaceuticals. Key Safety Requirements : 125459
: Characterizing potential immune responses to the viral vector or the new protein produced by the therapy.
